Cargando…

Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains

Background Highly pathogenic avian influenza A H5N1 viruses are widespread in different parts of the world and have evolved into clade 1 and 2 lineages. Their continuing circulation represents serious pandemic threat, spurring human vaccine development efforts. Initial clinical trials tested vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höschler, Katja, Gopal, Robin, Andrews, Nick, Saville, Melanie, Pepin, Stephanie, Wood, John, Zambon, Maria C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941882/ https://www.ncbi.nlm.nih.gov/pubmed/19453427 http://dx.doi.org/10.1111/j.1750-2659.2007.00033.x

Ejemplares similares

Broad Cross-Reactive Epitopes of the H5N1 Influenza Virus Identified by Murine Antibodies against the A/Vietnam/1194/2004 Hemagglutinin
por: Kobayashi-Ishihara, Mie, et al.
Publicado: (2014)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children
por: Chotpitayasunondh, Tawee, et al.
Publicado: (2008)

Risk Factors for Human Infection with Avian Influenza A H5N1, Vietnam, 2004
por: Dinh, Pham Ngoc, et al.
Publicado: (2006)

Diversity of Influenza A(H5N1) Viruses in Infected Humans, Northern Vietnam, 2004–2010
por: Imai, Hirotaka, et al.
Publicado: (2018)

Molecular Epidemiology of Clade 1 Influenza A Viruses (H5N1), Southern Indochina Peninsula, 2004–2007
por: Buchy, Philippe, et al.
Publicado: (2009)

A cell‐based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models
por: Cox, Rebecca J., et al.
Publicado: (2009)

Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam
por: Le, Thanh Hoa, et al.
Publicado: (2014)

Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020
por: Lewis, Nicola S., et al.
Publicado: (2021)

Human Infection with Highly Pathogenic Avian Influenza Virus (H5N1) in Northern Vietnam, 2004–2005
por: Hien, Nguyen Duc, et al.
Publicado: (2009)

Reproducibility of Serologic Assays for Influenza Virus A (H5N1)
por: Stephenson, Iain, et al.
Publicado: (2009)

Enhanced Immunogenicity, Mortality Protection, and Reduced Viral Brain Invasion by Alum Adjuvant with an H5N1 Split-Virion Vaccine in the Ferret
por: Layton, Robert Colby, et al.
Publicado: (2011)

Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013
por: Thor, Sharmi W., et al.
Publicado: (2015)

A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies
por: Temperton, Nigel J., et al.
Publicado: (2007)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets
por: Cox, Rebecca J., et al.
Publicado: (2015)

Influenza A H5N1 Clade 2.3.4 Virus with a Different Antiviral Susceptibility Profile Replaced Clade 1 Virus in Humans in Northern Vietnam
por: Le, Mai T. Q., et al.
Publicado: (2008)

Highly Pathogenic Avian Influenza H5N1, Thailand, 2004
por: Tiensin, Thanawat, et al.
Publicado: (2005)

Correction: Influenza A H5N1 Clade 2.3.4 Virus with a Different Antiviral Susceptibility Profile Replaced Clade 1 Virus in Humans in Northern Vietnam
por: Le, Mai T. Q., et al.
Publicado: (2008)

Novel Clade 2.3.4.4b Highly Pathogenic Avian Influenza A H5N8 and H5N5 Viruses in Denmark, 2020
por: Liang, Yuan, et al.
Publicado: (2021)

Risk Assessment for Highly Pathogenic Avian Influenza A(H5N6/H5N8) Clade 2.3.4.4 Viruses
por: Bui, Christine H.T., et al.
Publicado: (2021)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Structural and Antigenic Variation among Diverse Clade 2 H5N1 Viruses
por: Shore, David A., et al.
Publicado: (2013)

Experimental infection and pathology of clade 2.2 H5N1 virus in gulls
por: Gulyaeva, Marina A., et al.
Publicado: (2016)

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses
por: Szécsi, Judit, et al.
Publicado: (2006)

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
por: Stadlbauer, Daniel, et al.
Publicado: (2021)

Human Disease from Influenza A (H5N1), Thailand, 2004
por: Chotpitayasunondh, Tawee, et al.
Publicado: (2005)

Monoclonal Antibody Targeting Neutralizing Epitope on H5N1 Influenza Virus of Clade 1 and 0 for Specific H5 Quantification
por: He, Fang, et al.
Publicado: (2013)

Highly pathogenic avian influenza virus incursions of subtype H5N8, H5N5, H5N1, H5N4, and H5N3 in Germany during 2020-21
por: King, Jacqueline, et al.
Publicado: (2022)

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
por: Khurana, Surender, et al.
Publicado: (2018)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

The t + n + n System and 5H
por: Meister, M, et al.
Publicado: (2003)

Pathogenicity and Transmissibility of Clade 2.3.4.4h H5N6 Avian Influenza Viruses in Mammals
por: Zhang, Cheng, et al.
Publicado: (2022)

Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine
por: Burrell, Christopher, et al.
Publicado: (2008)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Phylogeography of influenza A H5N1 clade 2.2.1.1 in Egypt
por: Scotch, Matthew, et al.
Publicado: (2013)

Phylodynamics of avian influenza clade 2.2.1 H5N1 viruses in Egypt
por: Arafa, Abdelsatar, et al.
Publicado: (2016)

International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE
por: Laurie, Karen L., et al.
Publicado: (2015)

Lack of H5N1 Avian Influenza Transmission to Hospital Employees, Hanoi, 2004
por: Liem, Nguyen Thanh, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_re2okncjkgc3d1evgumrfc7gjl